NurExone Announces Closing of Non-Brokered Private Placement
Rhea-AI Summary
NurExone (OTCQB: NRXBF) closed a non-brokered private placement of 1,012,573 units at C$0.62 per unit, raising about C$627,795 in gross proceeds, subject to TSXV approval.
Each unit includes one share and one warrant at C$0.78, exercisable for 36 months, with an acceleration feature.
Positive
- Raised approximately C$627,795 in gross proceeds for general working capital
- Issued 1,012,573 units each with a share and a warrant at a premium exercise price of C$0.78
- Non-brokered structure with no finder’s fees paid, reducing transaction costs
- Warrants exercisable for 36 months may provide additional future capital inflow
Negative
- Immediate dilution from issuance of 1,012,573 new common shares
- Potential further dilution if 1,012,573 warrants are fully exercised at C$0.78
AI-generated analysis. How Rhea-AI works. Not financial advice.
TORONTO, Ontario and HAIFA, Israel, June 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that, subject to TSX Venture Exchange (“TSXV”) approval, it has closed a non-brokered private placement of 1,012,573 units (“Units”) at a price of C
Each Unit consists of (i) one common share in the capital of the Company (each, a “Common Share”), and (ii) one Common Share purchase warrant (each, a “Warrant”). Each Warrant entitles the holder thereof to purchase one Common Share at a price of C
Closing of the Offering is subject to receipt of all necessary regulatory approvals, including TSXV approval, and all securities issued under the Offering are subject to a statutory hold period of four months and one day from the closing date of the Offering.
About NurExone
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve damage. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitate the Company’s roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy.
For additional information and a brief interview, please watch Who is NurExone?, visit www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Russo Partners LLC
Investor and Media Relations – United States
215 Park Ave S, Suite 1905
New York, NY 10003
Phone: 212-845-4200
Email: nurexone@russopartnersllc.com
Dr. Eva Reuter
Investor Relations - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities laws (collectively, “forward-looking statements”). Forward-looking statements are often, but not always, identified by words such as “may”, “will”, “should”, “could”, “expect”, “intend”, “anticipate”, “believe”, “estimate”, “potential” and similar expressions.
Forward-looking statements in this press release include, without limitation, statements relating to: receipt of all required regulatory approvals, including final acceptance of the TSXV; the intended use of proceeds of the Offering for general working capital purposes; the potential exercise of the Warrants; the Company’s ability to accelerate the expiry date of the Warrants in accordance with their terms; and statements regarding the Company’s development, regulatory pathway, clinical trial roadmap, commercialization strategy and platform opportunities.
Forward-looking statements are based on management’s current expectations and assumptions as of the date of this press release, including assumptions regarding: the Company’s ability to obtain all required regulatory approvals, including final acceptance of the TSXV; the Company’s ability to use the proceeds of the Offering as currently intended; the continued availability of capital, personnel and third-party service providers on commercially reasonable terms; the Company’s ability to advance its development and regulatory plans; and the accuracy and continued relevance of the Company’s publicly disclosed scientific and regulatory information.
Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially, including, without limitation: the risk that required regulatory approvals, including final acceptance of the TSXV, may not be obtained on a timely basis or at all; the risk that the Company may not use the proceeds of the Offering as currently intended; financing and market risks; early-stage development risk; the risk that preclinical results may not be predictive of clinical results; regulatory review timing and outcomes; dependence on third-party collaborators and suppliers; intellectual property risks; competition and technological change; and the risks discussed under the heading “Risk Factors” on pages 44 to 51 of the Company’s annual information form dated August 27, 2024, a copy of which is available under the Company’s SEDAR+ profile at www.sedarplus.ca. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
